Health Care • Biotechnology: Pharmaceutical Preparations
$1.66 ▼ -0.10
(-5.68%)
MKT CAP: $75.4M • VOL: 165.7K
52W L $1 52W H $4
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
ACRV // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$84.1M | -$89.2M | -$67.1M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$77.9M | -$80.6M | -$60.4M |
| EBITDA (Normalized) | -$82.8M | -$87.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$63.7M | -$65.7M | -$42.6M |
| Capital Expenditures (CapEx) | $1.7M | $2.8M | — |
| Free Cash Flow (FCF) | -$65.3M | -$68.4M | -$42.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $41.5M | $39.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $112.5M | $176.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ACRV.